Norman D. Schwartz, Chairman and CEO of Bio-Rad Laboratories, Inc., filed a Form 4 on September 3, 2026, disclosing transactions in Bio-Rad Class A common stock on September 1, 2026, stemming from the vesting of restricted stock units.

Key Highlights

  • RSU vesting: 5,087 shares of Bio-Rad A Common Stock were acquired on September 1, 2026, at $0, upon the vesting of restricted stock units.
  • Tax withholding disposition: 2,336 shares of Bio-Rad A Common Stock were disposed of on September 1, 2026, at $380.96 per share, coded as an F (tax withholding) transaction.
  • Direct ownership after transactions: Schwartz directly holds 446,185 shares of Bio-Rad A Common Stock following the reported transactions.
  • Remaining RSUs: 3,005 restricted stock units tied to Bio-Rad A Common Stock remain outstanding following the transactions.
  • Roles: Schwartz is reported as Director, 10% Owner, and Chairman and CEO of Bio-Rad Laboratories, Inc.
  • Indirect holdings: Schwartz holds indirect interests in Bio-Rad A and B common stock through multiple trusts and a limited partnership, including 4,060,054 shares of Bio-Rad B Common Stock held by Blue Raven Partners, L.P.

Norman Schwartz's RSU Vesting and Share Withholding at Bio-Rad Laboratories

According to the filing, on September 1, 2026, Schwartz acquired 5,087 shares of Bio-Rad Class A common stock at $0 through the vesting of restricted stock units (transaction code M). The filing explains that 2,082 of those shares originated from a grant of 8,326 restricted stock units made on September 1, 2022, vesting in four equal annual installments beginning on the first anniversary of the grant date. The remaining 3,005 shares came from a grant of 12,020 restricted stock units made on September 1, 2023, on the same vesting schedule.

On the same date, the filing reports that 2,336 shares of Bio-Rad A Common Stock were disposed of at $380.96 per share under transaction code F, which denotes payment of an exercise price or tax liability by delivering or withholding securities. Following these two transactions, Schwartz directly holds 446,185 shares of Bio-Rad A Common Stock, according to the filing. Additionally, 3,005 restricted stock units representing a contingent right to receive Bio-Rad Class A common stock remain beneficially owned directly.

The filing also discloses a range of indirect beneficial ownership positions. These include 361,466 shares of Bio-Rad B Common Stock held directly, 13,006 shares of Bio-Rad B Common Stock held indirectly by spouse (with a disclaimer of beneficial ownership), and 4,060,054 shares of Bio-Rad B Common Stock held by Blue Raven Partners, L.P., of which Schwartz is both a limited and general partner, with a disclaimer of beneficial ownership except to the extent of his pecuniary interest. Multiple trusts, including the Alice N. Schwartz Revocable Trust and several David Schwartz trusts, hold additional shares of both Class A and Class B common stock, with Schwartz serving as trustee and similarly disclaiming beneficial ownership except to the extent of his pecuniary interest. The issuer is listed on NYSE as BIO and BIO.B.

What Was Disclosed

Schwartz reported the vesting of 5,087 restricted stock units into Bio-Rad A Common Stock and the withholding of 2,336 shares at $380.96 for tax purposes on September 1, 2026, along with his direct and indirect beneficial ownership positions across Bio-Rad Class A and Class B shares.